An observational study in Pulmonary Disease, Respiratory System Abnormalities and OSA, sponsored by University of California, San Diego. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by University of California, San Diego · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 406 studies in Lung Diseases with a site in United States — 66 open to participants now, 95 under way, 15 of them phase 3. Lung Diseases · United States.
Among the 406 studies in Lung Diseases with a site in United States, this one is the 93rd largest by planned enrollment of the 110 observational ones that give a count, is one of 20 that started in 2022, is one of 110 observational ones, reaches primary completion later than 20 of the 91 other live ones, and was the 328th registered.
1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.
Browse Lung Diseases studies →66 of the 406 studies in Lung Diseases with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Austria and 15 more countries
Ages 40–75
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Pfizer · Sites in United States, Australia, China and 11 more countries
Ages 18+
PureTech · Sites in United States, Canada
Ages 40+
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
406 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 89 · Phase 3 66 · Phase 4 15
First in 1978; this study’s year is marked. 20 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 200 across 315 observational studies indexed under Lung Diseases.
Median enrollment 81 across the 294 interventional studies, 198 across the 110 observational. Of the 284 that completed or were terminated, 109 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
164 of 406 have an industry lead sponsor. The 10 most frequent:
University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
University of California, San Diego has 4 studies filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
34 of the studies in Lung Diseases with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT05973773Phase 3Taiho Oncology, Inc.REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | 2027-05-27 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 406 studies in Lung Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Respiratory physiology involves a complex interplay of elements including control of breathing, respiratory drive, pulmonary mechanics, distribution of ventilation and gas exchange. Body position may also play an important role in respiratory mechanics. While effective methods exist for measuring these variables, they are typically measured in isolation rather than in combination. In pulmonary disease, decreasing mechanical stress and strain and optimizing transpulmonary pressure or the distending pressure across the lung, minimizing overdistention and collapse are central to clinical management. Obesity has a significant impact on pulmonary mechanics and is a risk factor for obstructive sleep apnea (OSA). However, our understanding of these elements is limited even in the general population. The investigators plan to use various validated methods to assess control of breathing, respiratory drive, distribution of ventilation and gas exchange to obtain a better understanding of underlying physiologic signatures in patients with and without obesity and the role of posture/position, with a secondary analysis comparing participants with and without obstructive sleep apnea.
Investigators will enroll 20 subjects with BMI 18.5-24.9 and 20 subjects with BMI 25 or more. The detailed inclusion criteria for subjects are listed below.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Position change
Other: Position change
Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
Distribution of ventilation
Change in regional ventilation distribution (ventral/dorsal) measured through electrical impedance tomography (EIT)
Time frame: 3 hours
Respiratory drive
Respiratory drive differences will be measured by mean desaturation (change from baseline percent oxygen saturation) following breath-hold maneuvers
Time frame: 3 hours
Respiratory drive
Respiratory drive differences will be assessed by the duration of maximal breath-hold (seconds)
Time frame: 3 hours
Respiratory drive
Respiratory drive will also be assessed by measurement of occlusion pressure (cm H2O) at 100 ms (P0.1) after the initiation of an inspiratory effort against a closed circuit.
Time frame: 3 hours
Pulmonary mechanics
Pulmonary mechanics will be measured by transpulmonary pressure (cmH2O)obtained from esophageal manometry (transpulmonary pressure= airway pressure- esophageal pressure)
Time frame: 3 hours
Dead space fraction
Dead space fraction will be calculated by partial pressure arterial/transcutaneous CO2 (PCO2) minus partial pressure of CO2 in mixed expired gas divided by the partial pressure of arterial/transcutaneous CO2
Time frame: 3 hours
Ventilatory ratio
Ventilatory ratio will be calculated as measured minute ventilation multiplied by the measured partial pressure of PCO2 divided (transcutaneous) by the predicted minute ventilation based on ideal body weight multiplied by the ideal PaCO2
Time frame: 3 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.
Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 53 months is above that.
Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Diego →